Treatment-related hypertension as a pharmacodynamic biomarker for the efficacy of bevacizumab in advanced pancreas cancer: a pooled analysis of 4 prospective …

S Pant, LK Martin, S Geyer, L Wei… - American journal of …, 2016 - journals.lww.com
Purpose: Phase III studies of bevacizumab in advanced pancreas cancer (APCA)
demonstrated no improvement in outcome. No validated biomarkers for bevacizumab …
被引用次数：18 相关文章
[HTML] nih.gov

[HTML][HTML] Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 …

S Pant, LK Martin, S Geyer, L Wei… - American journal of …, 2016 - ncbi.nlm.nih.gov
Purpose Phase III studies of bevacizumab in advanced pancreas cancer (APCA)
demonstrated no improvement in outcome. No validated biomarkers for bevacizumab …

Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 Prospective …

S Pant, LK Martin, S Geyer, L Wei… - … Journal of Clinical …, 2016 - ohiostate.elsevierpure.com
Purpose: Phase III studies of bevacizumab in advanced pancreas cancer (APCA)
demonstrated no improvement in outcome. No validated biomarkers for bevacizumab …
[PDF] researchgate.net

[PDF][PDF] Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer

S Pant, LK Martin, S Geyer, L Wei, K Van Loon… - Am J Clin …, 2016 - researchgate.net
Purpose—Phase III studies of bevacizumab in advanced pancreas cancer (APCA)
demonstrated no improvement in outcome. No validated biomarkers for bevacizumab …

Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 Prospective …

S Pant, LK Martin, S Geyer, L Wei… - … Journal of Clinical …, 2016 - mayoclinic.elsevierpure.com
Purpose: Phase III studies of bevacizumab in advanced pancreas cancer (APCA)
demonstrated no improvement in outcome. No validated biomarkers for bevacizumab …

Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer

S Pant, LK Martin, S Geyer, L Wei… - American Journal of …, 2016 - ingentaconnect.com
Purpose: Phase III studies of bevacizumab in advanced pancreas cancer (APCA)
demonstrated no improvement in outcome. No validated biomarkers for bevacizumab …

Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 Prospective …

S Pant, LK Martin, S Geyer, L Wei… - … journal of clinical …, 2016 - pubmed.ncbi.nlm.nih.gov
Purpose Phase III studies of bevacizumab in advanced pancreas cancer (APCA)
demonstrated no improvement in outcome. No validated biomarkers for bevacizumab …

Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 Prospective …

S Pant, LK Martin, S Geyer, L Wei… - American …, 2016 - mdanderson.elsevierpure.com
Purpose: Phase III studies of bevacizumab in advanced pancreas cancer (APCA)
demonstrated no improvement in outcome. No validated biomarkers for bevacizumab …

Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 Prospective …

S Pant, LK Martin, S Geyer, L Wei… - American Journal of …, 2016 - europepmc.org
Purpose Phase III studies of bevacizumab in advanced pancreas cancer (APCA)
demonstrated no improvement in outcome. No validated biomarkers for bevacizumab …